Skip to main content

Table 5 Total cost per patient per year and incremental cost-effectiveness

From: Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

 

T1DM

T2DMBOT

T2DMB/B

Degludec (BGN/year)

Glargine U100 (BGN/year)

Incremental cost (BGN/year)

Degludec (BGN/year)

Glargine U100 (BGN/year)

Incremental cost (BGN/year)

Degludec (BGN/year)

Glargine U100 (BGN/year)

Incremental cost (BGN/year)

Insulin

1296.67

1180.11

116.56

794.93

574.23

220.70

1574.88

1196.94

377.95

Hypoglycaemia events

1846.61

1893.80

−47.19

306.40

509.74

− 203.34

581.79

655.53

−73.74

Non-severe daytime events

19.42

19.42

0.00

15.02

15.02

0.00

16.35

19.69

−3.35

Non-severe nocturnal events

230.41

277.60

−47.19

284.26

443.94

− 159.68

211.17

281.56

−70.39

Severe events

1596.78

1596.78

0.00

7.11

50.78

−43.67

354.28

354.28

0.00

Total costs

3143.28

3073.92

69.37

1101.32

1083.97

17.35

2156.67

1852.47

304.21

QALYs

0.5722

0.5568

0.0154

0.7490

0.7055

0.0435

0.6893

0.6480

0.0413

ICER (cost/QALY)

4498.68

  

399.11

  

7365.22

  
  1. Abbreviations: B/B Basal-bolus, BGN Bulgarian Lev, BOT Basal oral therapy, ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life years, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus